$182.15
+2.35%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$179.96
From 52W high−17.64%
Volume1.98M
Market cap$39.04B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$179.96
From 52W high
−17.64%
Volume
1.98M
Market cap
$39.04B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−21.1x
P/E (TTM)
—
RSI (14)
38.9
MomentumView details →
1D Return
+2.35%
YTD Return
+129.77%
SummaryUpdated Jun 1, 2026
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company founded in 2014 and headquartered in Redwood City, California. The company went public in February 2020 and focuses specifically on developing novel therapies to treat RAS-addicted cancers. RAS proteins are among the most frequently mutated oncogenes in human cancers, found in approximately 30% of all cancers and up to 95% in certain cancer types like pancreatic cancer. Revolution Medicines has built a comprehensive pipeline of RAS pathway inhibitors and is currently advancing multiple drug candidates through clinical trials, with its lead program entering Phase 3 pivotal trials.
Similar companies
Latest newsMore news →
The EUROPEAN MEDICINES AGENCY’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.4d agoRevolution Medicines, Inc. began treating patients in the Phase 3 RASolute 309 trial evaluating RASONQUE (daraxonrasib) plus zoldonrasib as first-line treatment for metastatic RAS G12D pancreatic adenocarcinoma.15d agoIn late August 2026, the U.S. Food and Drug Administration approved daraxonrasib, a new KRAS-targeting therapeutic for previously treated pancreatic cancer developed by Revolution Medicines.29d ago